Tyra Biosciences (TYRA) Accumulated Expenses (2020 - 2026)

Tyra Biosciences has reported Accumulated Expenses for 7 years, with the latest figure at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 78.37% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 78.37% YoY), and the FY2025 full-year result was $5.5 million, down 14.23% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.0 million, down from $5.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $9.3 million in Q1 2025, with the low at $863000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $3.8 million across 5 years, with a median of $3.8 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 371.6% — and 2026, when it tumbled 78.37%.
• Tyra Biosciences' Accumulated Expenses stood at $1.0 million in 2022, then surged by 371.6% to $4.8 million in 2023, then surged by 33.07% to $6.5 million in 2024, then slipped by 14.23% to $5.5 million in 2025, then plunged by 63.64% to $2.0 million in 2026.
• The last three Accumulated Expenses figures came in at $2.0 million (Q1 2026), $5.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.